103 results about "Lung metastasis" patented technology

The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.

A medicine combination has the function of resisting lung cancer. The combination is mixed with rhizoma paridis saponin and milk vetch root amylose according to the weight ratio of 3 to 1. The rhizoma paridis is extracted by alcohol and then the rhizoma paridis extract is obtained through gradient elutriation of macroporous absorption resin alcohol; the milk vetch root is extracted by water and then the protein is settled and removed to get the milk vetch root amylose; the two extracts are mixed and the medicine is made. The MTT activities experiment in vitro with the MTT method has proven that the medicine combination can obviously control the growth of various lung cancer cells such as LA795 lung adenocarcinoma cell and the IC₅₀ can reach 26.73 ug/ml; the experiment of mouse with the lung cancer tumor has represented that the tumor constraint rate can reach 55.63 percent; in this way, lung transfer of hypodermic transplanted tumor of the mouse with the lung cancer tumor can be obviously controlled and the tumor cells can be brought to death; moreover, spleen index and thymus index can be promoted and the medicine is innocuous and has no side effect. In addition, compared with the raw materials, the medicine combination has high activity and clear function; moreover, the medicine can be made into different types.

A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.

The invention provides a cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling the blood coagulation factor VIII level to play an anti-tumor role, and application of the cyclopentanopolyhydrophenanthrene skeleton compound to preparation of drugs for treating blood coagulation factor VIII-mediated tumors, in particular to drugs for treating a blood coagulation factor VIII-mediated tumor which is blood coagulation factor VIII-mediated liver cancer. Experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit expression and secretion of HUVEC endothelial cells FVIII, inhibit HUVEC endothelial cell FVIII mediated hepatoma carcinoma cell proliferation, and inhibit adhesion of tumor cells and platelets mediated by FVIII secreted by HUVEC cells, and in-vivo experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit lung metastasis of liver cancer by inhibiting the level of FVIII.

The invention discloses a fusion gene line RAB22A-NoeFs for diagnosing and/or treating osteosarcoma. The first and second exons of the RAB22A gene are fused with the 54408036th to 54476718th positionof chromosome 20 after being inversed, the fusion gene line includes the following six fusion genes: RAB22A-NoeF1, RAB22A-NoeF2, RAB22A-NoeF3, RAB22A-NoeF4, RAB22A-NoeF5 and RAB22A-NoeF6, and the nucleotide sequences of the fusion genes are sequentially represented by SEQ ID NO:1-6. The six fusion genes of the fusion gene line RAB22A-NoeFs can promote the migration and invasion of osteosarcoma cells, wherein the RAB22A-NoeF1 has above functions, and also can promote the lung metastasis of the osteosarcoma cells. The fusion gene line RAB22A-NoeFs can be used as a specific therapeutic target forosteosarcoma, and has a great application prospect.

The invention provides a lung-targeting metastatic human hepatoma cell strain and an establishing method thereof. The lung-targeting metastatic human hepatoma cell strain is characterized in that the mother cell is a red fluorescent protein expression hepatoma cell HCCLM3-R; the cell is named as a lung-targeting metastatic human hepatoma cell strain HCCLM3-R-LM1 by classifying, has the preservation number of 3644, and has the following biological characteristics that the cell is in polygonal epithelium shape, grows clinging to the wall, loses contact growth inhibition, has a hypo-triploid caryogram with the chromosome number of 50-58, secretes AFP protein, and has lung-targeting metastatic clonal selection advantage. The establishing method comprises the following steps of: sieving by adopting nude mouse subcutis and liver orthotopic implantation tumour model autogenetic lung metastasis, and then carrying out in-vitro cloning, purifying and propagating on the lung-targeting metastatic human hepatoma cell. The invention has wide application potential and potential societal and economic benefits in basic research of hepatoma and clinic previous research of medicines.

The invention belongs to the field of pharmacy, and discloses the application of rusogenin fucopyranoside C in the pharmacy. The invention also provides the application of the rusogenin fucopyranoside C in the preparation of the medicine for resisting tumor metastasis, and more particularly relates to the application in the preparation of the medicine for generating tumour new blood vessels and inhibition of relative tumor metastasis. Being proved by the study of the invention, the rusogenin fucopyranoside C can effectively inhibit the growth, migration and adhesive ability, can inhibit lung metastasis of melanoma B16, and provides new selection in the application of preparing the medicine for resisting tumor metastasis.

The invention discloses a chemotherapy-immunotherapy combined drug and a preparation method and application thereof. A PTX micelle based on PEG-P (CL-DTC) is designed, and the technical effect of combination of the PTX micelle and vesicles (CPs-CDN) with asymmetric membrane structures of interferon-gene-carrying stimulating protein (STING) pathway agonist Cyclic Dinucleotide (CDN) in treatment of breast cancer (TNBC) is studied. The PTX micelle is simple in preparation method, small in particle size and high in drug loading capacity and has good stability and reduction responsiveness. Experiments show that after the PTX micelle is combined with the CPs-CDN, more BMDC maturation can be promoted, CD4<+> T and CD8<+> T cells in tumors and spleens are significantly increased, inhibitory Treg is reduced, tumor growth and lung metastasis are obviously inhibited, the lifetime of mice is prolonged, and the advantages of chemotherapy-immunotherapy are embodied.

The invention provides an animal model constructing method for studying epithelial and stromal hyalinosis of hepatocellular carcinoma. The method is characterized by the following steps: inoculating cancer cells to liver of an experimental animal in situ under guidance of ultrasonic equipment; and dynamically observing related index changes and lung metastasis conditions of epithelial and stromal hyalinosis. The method has the advantages that: the manufacturing process is simple and easy, has high success rate, and can be widely popularized and applied; and the manufactured animal mode can truly simulate the pathological process of clinical metastasis of hepatic carcinoma, and can dynamically reflect the developing process of the epithelial and stromal hyalinosis of the hepatic carcinoma.

The invention discloses siRNA capable of inhibiting MAT2A genetic expression and application of the siRNA. The positive-sense strand of siRNA MAT2A-1 capable of inhibiting the MAT2A genetic expression is shown as SEQ ID NO:2, and the antisense strand of the siRNA MAT2A-1 is shown as SEQ ID NO:3. The positive-sense strand of siRNA MAT2A-2 capable of inhibiting the MAT2A genetic expression is shown as SEQ ID NO:4, and the antisense strand of the siRNA MAT2A-2 is shown as SEQ ID NO:5. Lentivirus vector transfection liver cancer cells of lentivirus expression vector combination overexpression MAT1A genes built according to the siRNA inhibiting the MAT2A genetic expression successfully inhibit hepatocellular carcinoma angiogenesis, migration, invasion and lung metastasis, the nucleotide sequence of the MAT1A genes is shown as the 256th-144th bases of SEQ ID NO.1. The siRNA can be further applied to preparing medicine treating liver cancer diseases and has high theoretical and application value.

The present invention belongs to the field of traditional Chinese pharmaceutics, which relates to a traditional Chinese medicinal preparation for treating breast cancer and preparation method thereof.The present invention adopts supplementing qi, nourishing yin, regulating the thoroughfare and controlling vessels as therapeutic principle, which adopts the extracts of the following traditional Chinese medicine raw materials: radix astragali, Radix Codonopsis, bighead atractylodes rhizome, wolfberry, adenophora tetraphylla, epimedium sagittatum, Cornus officinalis, and auxiliary material to prepare a small preparation for treating breast cancer. By animal experiment and clinic trial, the results show that the preparation particles of the present invention can inhibit tumor growth and lung metastasis of tumor-bearing mice and enhance body antitumor enhance host anti-tumor immunity; the clinical studies showed that preparation particles of the present invention can obviously decrease sideeffects caused by a medicament for treating breast cancer and auxiliary treating endocrine, reduce adverse event, improve depression, and anxiety symptoms, and improve life quality of patient. The preparation of the present invention has the advantages of convenient administration, little dosage, no toxic side effect even long-term administration, and good evaluation.

The invention belongs to the technical field of medicine, and relates to a hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof. The hexamethoxyflavanone-rhamnosyl-rhamnoside is prepared by the following steps: carrying out solvent extraction and extraction separation on murraya jasminorage, carrying out silica gel column separation, carrying out further separation by semipreparative chromatography, concentrating, and carrying out freeze-drying to obtain the finished hexamethoxyflavanone-rhamnosyl-rhamnoside product. The antitumor activity evaluation detects that the hexamethoxyflavanone-rhamnosyl-rhamnoside has low cytotoxicity; the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on the adhesion of colon cancer cells HT-29 and Fn (fibronectin) and the adhesion of HUVECs (human umbilical vein endothelial cells); the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on migration capacity (scratch heating experiment) and invasion capacity of HT-29; and the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on mouse in-vivo B16-F10 lung transfer. Therefore, the hexamethoxyflavanone-rhamnosyl-rhamnoside has tumor transfer inhibition activity, can be used for preparing anticancer drugs, and has favorable development and application prospects.

The invention discloses an application of a polypeptide Kp-10 in preparation of a medicine for treating and preventing osteosarcoma. The amino acid sequence of the polypeptide Kp-10 is DSSDSSDSSDSSDSSDSSYNWNSFGLRF. Researches find that expression of GPR54/KiSS-1 in osteosarcoma tissues is obviously lower than that in normal tissues beside the tumor tissues, and is highly related to clinical prognosis, and the polypeptide Kp-10 and a receptor GPR54 of the polypeptide Kp-10 can inhibit proliferation and migration capacity and lung metastasis capacity of osteosarcoma cells, so that the polypeptide Kp-10 can be used for preparing medicines for treating and preventing osteosarcoma, and a new thought is provided for exploration of osteosarcoma targeted medicine.

Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin [alpha]5[beta]1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin [alpha]5[beta]1-mediated Rac1/PAK signaling to weaken cell-cell contacts. Subsequently, cANGPTL4 is associated with and declusters VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption. In vivo vascular permeability and metastatic assays performed using ANGPTL4-knockout and wild-type mice injected with either control or ANGPTL4-knockdown tumors confirmed that cANGPTL4 induced vascular leakiness and facilitated lung metastasis in mice. Therefore, our findings elucidate how cANGPTL4 induces endothelial disruption. Our findings have direct implications for targeting cANGPTL4 to treat cancer and other vascular pathologies.

The invention provides a preparation method for a liver-restoring tablet. The liver-restoring tablet is prepared from the bulk drugs consisting of 800 g of isatis root, 166 g of oriental wormwood, 266 g of curcuma tuber, 266 g of Chinese magnoliavine, 266 g of licorice, 133 g of Chinese angelica, 400 g of milk vetch and 200 g of acanthopanax root through supercritical extraction. With the preparation method, the content of the bulk drugs in the liver-restoring tablet is greatly increased, and the dose of the tablet is reduced. The invention further provides application of the liver-restoring tablet in preparation of drugs used for inhibiting cell proliferation of the mouse melanoma lung metastasis strain B16-F10.

The invention discloses a lung metastasis prediction method for patients with limb soft tissue sarcoma, and the method comprises the steps: S1, carrying out the feature extraction of all to-be-testedobjects through employing a standard shooting value of a PET image, wherein the features comprises an SUV feature and a texture feature; s2, carrying out feature extraction on all tested clinical information by using a one-hot encoding method; and S3, performing feature contribution degree sorting on all the features by using a random forest algorithm, fusing the high contribution degree features,and constructing a lung metastasis prediction model of the patient with the limb soft tissue sarcoma by using a BP neural network. The lung metastasis prediction method can predict the lung metastasis condition of patients with limb soft tissue sarcoma more accurately by using fewer patient characteristics.

The invention provides application of a rotundic acid derivant in preparation of a medicine for preventing and treating tumour metastasis. An in vitro experiment proves that the rotundic acid derivant disclosed by the invention has significant inhibition effects on proliferation, adhesion, migration and the like of tumor cells, and is safe and low-toxicity to normal cells of a human body. An in vivo animal experiment proves that experimental lung metastasis of B16-F10 melanoma of mice can be effectively reduced, and a preferable tumour metastasis prevention effect is prompted. The rotundic acid derivant disclosed by the invention can be applied to a medicine for preventing the tumour metastasis, so that new application of the rotundic acid derivant to prevention and treatment of tumors is developed, and a new choice is provided for developing a new drug for treating the tumour metastasis and preventing postoperative re-metastasis of malignant tumour; moreover, the rotundic acid derivant has more obvious pharmacological activity.

The invention relates to the technical field of medical bioengineering, in particular to an anti-human YKL-40 neutralizing monoclonal antibody. The amino acid sequence of a heavy chain variable regionof the monoclonal antibody is shown as SEQ ID NO:1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO:2. According to the invention, uniquesequence information of the monoclonal antibody is provided, and a hybridoma cell strain secreting the monoclonal antibody and application of the monoclonal antibody and the hybridoma cell strain inpreparation of drugs for inhibiting lung metastasis of liver cancer are also provided.

The invention relates to the field of pharmaceutical preparations, and relates to a calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and a prodrug of a natural drug and a preparation method for the nano-drug co-delivery system. According to the nano-drug co-delivery system, nanoparticles prepared from a biodegradable lipid material are taken as carriers, and the phosphorylated prodrug PIC-POOH of the natural drug piceatannol (PIC) is physically entrapped, and the low molecular weight heparin (LMWH) adsorbs on the outer layers of the carriers by static electricity; and a nano preparation concentrates at a tumor site by utilizing the long circulating performance of the nano preparation and the enhanced permeability and retention (EPR) effect ofa solid tumor tissue, a related pathway for tumor cell metastasis is then regulated, angiogenesis is inhibited, and the anti-tumor metastasis action is exerted. Proved by assays, the nano-drug co-delivery system can inhibit the epithelial-mesenchymal transition (EMT) progress of tumor cells; proved by a tube formation assay, the nano-drug co-delivery system can significantly inhibit tumor angiogenesis; proved by in vivo administration evaluation, the nano-drug co-delivery system can reduce formation of lung metastasis on a mice model, and prolongs the survival time of tumor-bearing mice; and the nano-drug co-delivery system has an obvious anti-tumor metastasis effect, especially reduces triple negative breast cancer metastasis, and has high safety.

The present invention relates to a method and composition for treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NFκB signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4/NFκB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3.

The invention provides a pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state and a preparation method and application thereof. The photosensitive dye has a structure shown in a general formula I. The pentamethine-cyanine-dye photosensitive dye with long lifetime of excited state can have relatively high singlet oxygen quantum yield and relatively long lifetime of excited state. Under the excitation of near-infrared light, the photodynamic killing can be carried out on normoxic and hypoxic cancer cells. Meanwhile, the pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state possesses a good application prospect in the aspects of treating solid tumors in vivo and inhibiting lung metastasis of cancer cells.